Save Sight Registries set global benchmark for research
in Ageing, Clinical Trials, Macular Degeneration, News, Ocular Surface Disease, Registries
9 Sep 2015
After eight years of development and experience, the Save Sight Registries (SSR) at Save Sight Institute has been endorsed as a preferred data collection system by the International Consortium for Health Outcomes Measurement, ICHOM
Following ICHOM’s development of a “comparable and measurable data set for benchmarking and learning” for macular degeneration by leading clinicians in the field, patient representatives and global registry leaders, our system has been endorsed as a preferred supplier to ensure the accurate collection of this data.
The SSR is an initiative of Save Sight Institute that collects real-world clinical data on macular degeneration patient outcomes. To date, the registry has accumulated over 120,000 treatments on 5000 eyes, after rapidly developing international interest with its unique patient focus.
According to the director of the Macular Research Group at Save Sight Institute, Professor Mark Gillies, “For patients, the simplified graphical outputs of their treatment journey helps them to understand the consequences of various treatment approaches”.
The initiative seeks to promote improved outcomes for patients and organisations, particularly in the treatment of wet age-related macular degeneration, diabetic macular edema. and keratoconus.
The statistical functionality of the SSR allow clinicians to conduct self-audits. “Armed with these reports, I believe that my colleagues will see the value of the program for their patients and their practice, amongst many others” said one clinician.
It is expected that by collecting measurable standardised outcomes, comparisons at a global level through the registry will lead to advancements in patient care by focusing on patient- centered results.